Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials

Katie Linden, Jonathan Mailey, Aileen Kearney, Ian B A Menown, Katie Linden, Jonathan Mailey, Aileen Kearney, Ian B A Menown

Abstract

Introduction: A large number of important clinical trials in cardiology were published or presented at major international conferences during 2019. This paper aims to offer a concise overview of these significant advances and to put them into clinical context.

Methods: Trials presented at the major international cardiology meetings during 2019 were reviewed including The American College of Cardiology (ACC), Euro PCR, The European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), and the American Heart Association (AHA). In addition to this a literature search identified several other publications eligible for inclusion based on their relevance to clinical cardiology, their potential impact on clinical practice and on future guidelines.

Results: A total of 70 trials met the inclusion criteria. New interventional and structural data include trials examining use of drug-coated balloons in patients with acute myocardial infarction (MI), interventions following shockable cardiac arrest, mechanical circulatory support in cardiogenic shock complicating MI, intervention in stable coronary artery disease, surgical or percutaneous revascularisation strategies in left main coronary artery disease, revascularisation strategy in ST elevation MI, transcatheter aortic valve replacement in low-risk patients, and percutaneous mitral or tricuspid valve interventions. Preventative cardiology data included the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin), proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (evolocumab), bempedoic acid, and novel approaches to the management of hypertension. Antiplatelet data included trials evaluating both the optimal length of course and combination of antiplatelet agents and regimes including combination antithrombotic therapies for patients with atrial fibrillation. Heart failure data included trials of sacubitril-valsartan in heart failure with preserved ejection fraction and the use of SGLT2 inhibitors in patients with heart failure but without diabetes. Electrophysiology data included trials examining alcohol in atrial fibrillation and the use of wearable fitness devices for identifying atrial fibrillation.

Conclusion: This article presents key clinical trials completed during 2019 and should be valuable to clinicians and researchers working in cardiology.

Keywords: Acute coronary syndrome; Anticoagulation; Atrial fibrillation; Cardiology; Coronary revascularisation; Heart failure; Lipids; Mitral clip; Myocardial infarction; Transcatheter aortic valve implantation.

Figures

Fig. 1
Fig. 1
a Flattened view of the cobalt chromium stent platform (small vessel model). b Details of the straight and curved link connectors. c Comparison with LEADERS (historical control), with propensity matching and landmark analysis at day 3 for the primary endpoint of major adverse cardiac events at 9 months [3]
Fig. 2
Fig. 2
Kaplan–Meier estimates of the 5-year outcomes in the NOBLE intention to treat population Reprinted from Holm et al. [8], with permission from Elsevier
Fig. 3
Fig. 3
Computed tomography image demonstrating hypoattenuation of the right cusp of TAVI prosthesis consistent with a focal area of thrombus
Fig. 4
Fig. 4
Leaflex™ performer catheter system. Image courtesy of Pi-Cardia (Rehovot, Israel)
Fig. 5
Fig. 5
The Moderato device, which reduces blood pressure using cardiac neuromodulation therapy. Image permitted and courtesy of Orchestra BioMed (New Hope, PA, USA)

References

    1. Urban P, Mehran R, Morice MC, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J. 2019;40(31):2632–2653.
    1. Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020;382(13):1208–1218.
    1. Menown IBA, Mamas MA, Cotton JM, et al. First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry. Int J Cardiol Heart Vasc. 2020;26:100472.
    1. Buiten R, Ploumen E, Zocca P, et al. Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels. J Am Med Assoc Cardiol. 2019;4(7):659–669.
    1. Zaman A, de Winter RJ, Kogame N, et al. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. Lancet. 2019;393(10175):987–997.
    1. Xu B, Saito Y, Baumbach A, et al. 2-year clinical outcomes of an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent compared with a durable-polymer everolimus-eluting stent. JACC Cardiovasc Interv. 2019;12(17):1679–1687.
    1. Stone GW, Kappetein AP, Sabik JF, et al. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med. 2019;381:1820–1830.
    1. Holm NR, Mäkikallio T, Lindsay MM, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet. 2020;395(10219):191–199.
    1. Thuijs DJ, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394:1325–1334.
    1. Vos N, Fagel N, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction. J Am Coll Cardiol Cardiovasc Interv. 2019;12(17):1691–1699.
    1. Burzotta F, Leone AM, Aurigemma C, et al. Fractional flow reserve or optical coherence tomography to guide management of angiographically-intermediate coronary stenosis: a single-center trial. J Am Coll Cardiol Cardiovasc Interv. 2020;13(1):49–58.
    1. Ali ZA, Nef H, Escaned J, et al. Safety and effectiveness of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: the disrupt CAD II study. Circn Cardiovasc Interv. 2019;12(10):e008434.
    1. Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381:1411–1421.
    1. Hochman J. International study of comparative health effectiveness with medical and invasive approaches. Presented at the American Heart Association Annual Scientific Sessions, 16 November 2019; Philadelphia, PA.
    1. Bangalore S. International study of comparative health effectiveness with medical and invasive approaches–chronic kidney disease. Presented at the American Heart Association Annual Scientific Sessions, 16 November 2019; Philadelphia, PA.
    1. Thourani VH. Five-year outcomes from PARTNER 2A trial: transcatheter vs. surgical aortic valve replacement in intermediate-risk patients. Presented at the Transcatheter Cardiovascular Therapeutics meeting, 28 September 2019; San Francisco, CA.
    1. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380(18):1706–1715.
    1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–1705.
    1. Makkar RR. PARTNER 3 low-risk computed tomography substudy: subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves. Presented at the Transcatheter Cardiovascular Therapeutics meeting, 27th September 2019; San Francisco, CA.
    1. Dangas GD, Tijssen JG, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–129.
    1. Lanz J, Kim WK, Walther T, et al. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. Lancet. 2019;394:1619–1628.
    1. Van Belle Eric, Vincent Flavien, Labreuche Julien, Auffret Vincent, Debry Nicolas, Lefèvre Thierry, Eltchaninoff Helene, Manigold Thibaut, Gilard Martine, Verhoye Jean-Phillipe, Himbert Dominique, Koning Rene, Collet Jean-Phillipe, Leprince Pascal, Teiger Emmanuel, Duhamel Alain, Cosenza Alessandro, Schurtz Guillaume, Porouchani Sina, Lattuca Benoit, Robin Emmanuel, Coisne Augustin, Modine Thomas, Richardson Marjorie, Joly Patrick, Rioufol Gilles, Ghostine Said, Bar Olivier, Amabile Nicolas, Champagnac Didier, Ohlmann Patrick, Meneveau Nicolas, Lhermusier Thibaut, Leroux Lionel, Leclercq Florence, Gandet Thomas, Pinaud Frédéric, Cuisset Thomas, Motreff Pascal, Souteyrand Géraud, Iung Bernard, Folliguet Thierry, Commeau Philippe, Cayla Guillaume, Bayet Gilles, Darremont Olivier, Spaulding Christian, Le Breton Hervé, Delhaye Cédric. Balloon-Expandable Versus Self-Expanding Transcatheter Aortic Valve Replacement. Circulation. 2020;141(4):243–259.
    1. Makkar RR, Yoon SH, Leon MB, et al. Association between transcatheter aortic valve replacement for bicuspid vs tricuspid aortic stenosis and mortality or stroke. J Am Med Assoc. 2019;321:2193–2202.
    1. Baumbach A, Hildick-Smith D, Mylotte D, et al. Safety, feasibility, and acute performance of the Leaflex Performer when used pre-TAVI in aortic stenosis patients: the Leaflex feasibility study. Presented at EuroPCR, 22nd May 2019; Paris, France.
    1. Kang DH, Park SJ, Lee SA, et al. Early surgery or conservative care for asymptomatic aortic stenosis. N Engl J Med. 2020;382:111–119.
    1. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379(24):2297–2306.
    1. Iung B, Armoiry X, Vahanian A, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail. 2019;21(12):1619–1627.
    1. Stone G, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379(24):2307–2318.
    1. Mack MJ. COAPT: 3-year outcomes from a randomized trial of the MitraClip in patients with heart failure and severe secondary mitral regurgitation. Presented at the Transcatheter Cardiovascular Therapeutics meeting, 28 September 2019; San Francisco, CA.
    1. Asch FM. Heart Failure and secondary mitral regurgitation: echocardiographic outcomes from the COAPT Trial. Presented at The American College of Cardiology Scientific Sessions, 17 March 2019; New Orleans, LA.
    1. . A clinical evaluation of the safety and effectiveness of the MitraClip system in the treatment of clinically significant functional mitral regurgitation (Reshape-HF2). . Accessed 20 Mar 2020
    1. Hausleiter J. Early procedural outcomes from subjects treated with next-generation MitraClip (NTR/XTR) system: initial observations from the Global EXPAND study. Presented at EuroPCR, 21 May 2019; Paris, France.
    1. Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74(24):2998–3008.
    1. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394(10213):2002–2011.
    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
    1. Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628–2639.
    1. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.
    1. Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138(5):458–468.
    1. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139:2528–2536.
    1. Aminian A, Zajichek A, Arterburn D, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. J Am Med Assoc. 2019;322(13):1271–1282.
    1. Schwalm JD, McCready T, Lopez-Jaramillo P, et al. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster randomised controlled trial. Lancet. 2019;394(10205):1231–1242.
    1. Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2019. 10.1093/eurheartj/ehz754.
    1. White WB, Wakefield DB, Moscufo N, et al. Effects of intensive versus standard ambulatory blood pressure control on cerebrovascular outcomes in older people (INFINITY) Circulation. 2019;140(20):1626–1635.
    1. Kuck KH. MODERATO II: a double-blind randomized trial of cardiac neuromodulation therapy in patients with hypertension. Presented at Transcatheter Cardiovascular Therapeutics meeting 2019, 28 September 2019; San Francisco, CA.
    1. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107.
    1. Jukema JW, Szarek M, Zijlstra LE, et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74(9):1167–1176.
    1. Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–1539.
    1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
    1. Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS) J Am Coll Cardiol. 2019;74(20):2452–2462.
    1. Linden K, McQuillan C, Brennan P, Menown IBA, et al. Advances in clinical cardiology 2018: a summary of key clinical trials. Adv Ther. 2019;36(7):1549–1573.
    1. Scott Wright R. Inclisiran for subjects with ACSVD and elevated low density lipoprotein cholesterol—ORION-10. Presented at the American Heart Association Annual Scientific Sessions 2019, 16 November 2019. Philadelphia, PA.
    1. Ray KK. Impact of inclisiran on LDL-C over 18 months in patients with ASCVD or risk equivalent—results of the phase 3 ORION-11 trial. Presented at the European Society of Cardiology Congress 2019, 2 September 2019. Paris, France.
    1. Goldberg AC. Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia and high cardiovascular risk: the CLEAR wisdom trial. Presented at American College of Cardiology Annual Scientific Sessions 2019, 18 March 2019; New Orleans, LA.
    1. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–1032.
    1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
    1. Budoff MJ. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy—EVAPORATE. Presented at the American Heart Association Annual Scientific Sessions 2019, 18 November 2019. Philadelphia, PA.
    1. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
    1. Tardif Jean-Claude, Kouz Simon, Waters David D., Bertrand Olivier F., Diaz Rafael, Maggioni Aldo P., Pinto Fausto J., Ibrahim Reda, Gamra Habib, Kiwan Ghassan S., Berry Colin, López-Sendón José, Ostadal Petr, Koenig Wolfgang, Angoulvant Denis, Grégoire Jean C., Lavoie Marc-André, Dubé Marie-Pierre, Rhainds David, Provencher Mylène, Blondeau Lucie, Orfanos Andreas, L’Allier Philippe L., Guertin Marie-Claude, Roubille François. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine. 2019;381(26):2497–2505.
    1. Shah B. Effects of acute colchicine administration prior to percutaneous coronary intervention: the COLCHICINE-PCI randomized trial. Presented at the American Heart Association Annual Scientific Sessions 2019, 17 November 2019. Philadelphia, PA.
    1. Bjoerklund. SWEDEHEART—Secondary prevention medication after coronary artery bypass surgery and long-term mortality: a longitudinal population-based study from the SWEDEHEART registry. Presented at the European Society of Cardiology Congress 2019, 3 September 2019. Paris, France.
    1. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032–2042.
    1. Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. J Am Med Assoc. 2019;321:2428–2437.
    1. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs. 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. J Am Med Assoc. 2019;321:2414–2427.
    1. Kirtane AJ. EVOLVE Short DAPT: a single arm study of 3-month DAPT in patients at high bleeding risk treated with a bioabsorbable polymer-based everolimus-eluting stent. Presented at Transcatheter Cardiovascular Therapeutics meeting 2019, 26 September 2019; San Francisco, CA.
    1. Franzone A, McFadden E, Leonardi S, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am Coll Cardiol. 2019;74(18):2223–2234.
    1. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381:1309–1320.
    1. Schüpke S, Neumann F, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524–1534.
    1. National Institute for Health Care and Excellence (2020). Guideline acute coronary syndromes. . Accessed 20 Mar 2020.
    1. Claassens DM, Vos GJ, Bergmeyer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621–1631.
    1. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509–1524.
    1. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335–1343.
    1. Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019;380:1825–1833.
    1. Lemkes JS, Janssens GN, van der Hoeven NW, et al. Coronary angiography after cardiac arrest without ST-segment elevation. N Engl J Med. 2019;380:1397–1407.
    1. Hausenloy DJ, Kharbanda RK, Moller UK, et al. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. Lancet. 2019;394:1415–1424.
    1. Perera D. PROTECCT: a randomized trial of emergency CTA in patients with possible ACS and intermediate levels of HS-troponin elevation. Presented at Transcatheter Cardiovascular Therapeutics meeting 2019, 27 September 2019; San Francisco, CA.
    1. Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139(10):1249–1258.
    1. Amin AP, Spertus JA, Curtis JP, et al. The evolving landscape of Impella use in the United States among patients undergoing percutaneous coronary intervention with mechanical circulatory support. Circulation. 2020;141:273–284.
    1. Voskoboinik A, Prabhu S, Ling LH, et al. Alcohol and atrial fibrillation: a sobering review. J Am Coll Cardiol. 2016;68:2567–2576.
    1. Voskoboinik A, Kalman JM, Nicholls T, et al. Impact of alcohol abstinence in moderate drinkers with atrial fibrillation: results from the alcohol-AF randomized controlled trial. Presented at American College of Cardiology Annual Scientific Sessions 2019, 18 March 2019; New Orleans, LA.
    1. Matsumura-Nakano Y, Shizuta S, Komasa A, et al. An open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond one year after coronary stent implantation: the OAC-ALONE study. Circulation. 2019;139:604–616.
    1. Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103–1113.
    1. Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20):1909–1917.
    1. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–548.
    1. Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. J Am Med Assoc. 2019;322:1085–1095.
    1. McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan, versus valsartan in women compared to men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020;141:338–51.
    1. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
    1. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
    1. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). . Accessed on 07 Jan 2020.
    1. Halliday BP, Wassall R, Lota AS. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open label, pilot, randomised trial. Lancet. 2019;393(10166):61–73.
    1. Shavelle DM. Pulmonary artery pressure-guided therapy for ambulatory heart failure patients in clinical practice; 1-year outcomes from the CardioMEMS post-approval study. Presented at American College of Cardiology Annual Scientific Sessions 2019, 17 March 2019; New Orleans, LA.
    1. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Eur Heart J. 2015;36(41):2793–2867.
    1. Haanschoten D. Long-term outcome of the defibrillator after primary angioplasty (DAPA) trial. Presented at European Society of Cardiology Congress, 3 September 2019. Paris, France.
    1. Tarakji KG, Mittal S, Kennergren C, et al. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med. 2019;380(20):1895–1905.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する